Why the study?
The role of direct-acting oral anticoagulants compared with the standard of low-molecular-weight heparin in cancer patients with venous thromboembolism remains unclear.
Do direct factor Xa inhibitors reduce recurrent VTE compared to low-molecular-weight heparin in cancer patients with VTE?
Do direct factor Xa inhibitors reduce recurrent VTE compared to low-molecular-weight heparin in cancer patients with VTE?
Direct factor Xa inhibitors are more effective than LMWH for preventing recurrent VTE in cancer patients, with comparable major bleeding but slightly higher minor bleeding.
No takes yet. Share an insight, caveat, or question.
Observational data on factor Xa inhibitors for cancer VTE warrant caution; leaves open need for randomized confirmation.
Yang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: